Introduction A strong IND submission is more than a collection of separate documents. We often see audit and FDA observations arise when nonclinical, CMC, and
Submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) is a defining moment for biotech innovators. It marks the